Sign up to save your podcasts
Or
Share Lead: The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Lead: The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021
The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021
Addiction
Buprenorphine labeling identifies 16 mg as the “target dose,” supported by prior evidence that higher doses (≥16 mg) were associated with increased retention in treatment. Studies comparing doses above 16 mg to 16 mg, particularly in the era of fentanyl, have been very limited. The authors conducted a cohort study to look at retention for those receiving 24, 32, and 40 mg compared to 16 mg. Overall, higher doses were associated with increased retention, as follows: 1) 24 mg was more effective than 16 mg at 1 (aOR=1.52) and 18 months (aOR=1.17), 2) 32 mg was more effective than 24 mg at 6 (aOR=1.06), 12 (aOR=1.09), and 18 months (aOR=1.12), and 3) 40 mg was more effective than 24 mg at 12 (aOR=1.10) and 18 months (aOR=1.18). The authors suggest updates to label language and recommendations are prudent, while also supporting more research on long-term treatment with these higher doses.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
View all episodes
By American Society of Addiction Medicine
4.9
77 ratings
The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021
Addiction
Buprenorphine labeling identifies 16 mg as the “target dose,” supported by prior evidence that higher doses (≥16 mg) were associated with increased retention in treatment. Studies comparing doses above 16 mg to 16 mg, particularly in the era of fentanyl, have been very limited. The authors conducted a cohort study to look at retention for those receiving 24, 32, and 40 mg compared to 16 mg. Overall, higher doses were associated with increased retention, as follows: 1) 24 mg was more effective than 16 mg at 1 (aOR=1.52) and 18 months (aOR=1.17), 2) 32 mg was more effective than 24 mg at 6 (aOR=1.06), 12 (aOR=1.09), and 18 months (aOR=1.12), and 3) 40 mg was more effective than 24 mg at 12 (aOR=1.10) and 18 months (aOR=1.18). The authors suggest updates to label language and recommendations are prudent, while also supporting more research on long-term treatment with these higher doses.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
More shows like This Week in Addiction Medicine from ASAM
View all
NEI Podcast
130 Listeners
JAMA Clinical Reviews
481 Listeners
AFP: American Family Physician Podcast
690 Listeners
Frankly Speaking About Family Medicine
254 Listeners
White Coat Investor Podcast
2,411 Listeners
The Curbsiders Internal Medicine Podcast
3,324 Listeners
Core IM | Internal Medicine Podcast
1,092 Listeners
Addiction Medicine: Beyond the Abstract
28 Listeners
Psychopharmacology and Psychiatry Updates
282 Listeners
The Carlat Psychiatry Podcast
554 Listeners
The Curious Clinicians
362 Listeners
The Curbsiders Addiction Medicine Podcast
116 Listeners
Addiction Medicine Journal Club
31 Listeners
PsychRounds: The Psychiatry Podcast
102 Listeners